Sueki Ayana, Kaya Daisuke, Nagamatsu Shinsaku, Yamamoto Chisa, Ohta Kohei, Matsuo Yuya, Nishio Yuya, Komeda Yusuke, Kikukawa Shoma, Matsuura Kyohei, Matsuo Hideki, Uejima Masakazu, Moriya Kei
Department of Gastroenterology, Nara Prefecture General Medical Center, Japan.
Department of Endocrinology and Metabolism, Nara Prefecture General Medical Center, Japan.
Intern Med. 2025 Feb 1;64(3):387-391. doi: 10.2169/internalmedicine.3896-24. Epub 2024 Jun 27.
This case report describes a patient who received hormone replacement therapy for secondary panhypopituitarism and subsequently developed diabetes. His physician decided to discontinue growth hormone (GH) replacement, which was previously deemed contraindicated. Following the diagnosis of fatty liver, the patient began to exhibit liver damage that progressed over the ensuing years, ultimately leading to cirrhosis. Common factors linked to cirrhosis were excluded, leading to the belief that GH deficiency over several years was the primary contributor to cirrhosis. Therefore, when treating patients with GH insufficiency and diabetes, clinicians should carefully consider the potential implications of GH replacement therapy.
本病例报告描述了一名因继发性全垂体功能减退接受激素替代治疗并随后患上糖尿病的患者。他的医生决定停止此前被认为禁忌的生长激素（GH）替代治疗。在诊断出脂肪肝后，患者开始出现肝脏损伤，并在随后几年中逐渐加重，最终发展为肝硬化。排除了与肝硬化相关的常见因素后，认为数年的GH缺乏是肝硬化的主要促成因素。因此，在治疗GH不足和糖尿病患者时，临床医生应仔细考虑GH替代治疗的潜在影响。
